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ABSTRACT
Introduction: Group B streptococcus (GBS), or Streptococcus agalactiae, is a bacterium 
found in normal human microbiota. However, it may cause neonatal pneumonia, sepsis, 
and meningitis. Genital colonization in pregnant women is associated with a higher 
risk of preterm birth. The treatment of choice is antibiotic therapy with beta-lactams, 
but in the case of multidrug-resistance, erythromycin and clindamycin can be used.
Methods: This study evaluated bacterial cultures in the period from 2014 to 2015 from 
a group of 29,875 pregnant women. GBS colonization and resistance to erythromycin 
and clindamycin were investigated.
Results: Positive cultures were found in 26.8% and 26.1% of the samples in 2014 
and 2015, respectively. Levels of resistance to erythromycin and clindamycin were, 
respectively, 2.4% and 5.5% in 2014 and 3.2% and 6.5% in 2015.
Conclusion: The investigation of GBS colonization and the evaluation of GBS resistance 
to erythromycin and clindamycin are of extreme relevance, given the increasing 
incidence of bacterial resistance, risks of preterm birth, and serious consequences 
to newborns, representing a global health problem.
Keywords: Streptococcus agalactiae; erythromycin; clindamycin; prenatal care; drug 
resistance, microbial
Group B streptococcus (GBS), or Streptococcus agalactiae, is a Gram-positive, 
coccoid bacterium with a chain-shaped arrangement, a beta-hemolytic strain, 
and an invasive potential. It is a nutritionally demanding microorganism 
that grows well in culture media enriched by the addition of blood, being 
facultatively anaerobic and homofermentative. Some species multiply faster 
in an atmosphere rich in carbon dioxide (CO2), about 5 to 10%1.
GBS  is part of the normal human mucosal microbiota. It is the main cause 
of neonatal pneumonia, sepsis, and meningitis, as well as the pathogen of 
serious diseases in adults, contributing to morbidity and mortality in this group 
of individuals2-4.
The normal cervicovaginal microbiota is one of the defense mechanisms 
against the growth and rise of this pathogenic microorganism. Due to the 
production of lactic acid, hydrogen peroxide, and other antimicrobial substances, 
lactobacilli play an important role in the local defense. In pregnancy, imbalance 
of the vaginal microbiota favors colonization by microorganisms associated 
with pregnancy complications5.
Therefore, S. agalactiae infection is an important cause of severe invasive 
disease in newborns, with sepsis and pneumonia being the most frequent 
ones. Infections such as meningitis, osteomyelitis, and septic arthritis may also 
occur. Most of these start early and occur in the first week of life. However, 
infections may manifest late, up to the third month of life, especially in cases 
of meningitis. Approximately 15 to 30% of children who survive S. agalactiae 
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meningitis have neurological sequelae, including 
blindness, deafness, and severe mental retardation4,6.
For this reason, genital colonization of pregnant 
women with GBS has been associated with an 
increased risk of preterm birth, and newborns of 
colonized mothers are at higher risk of contracting 
infections by this microorganism7. There is also 
a greater risk of systemic dissemination of the 
microorganism in colonized preterm children as they 
have immature immune system6,8,9. Studies have 
demonstrated that prophylactic procedures such as 
intrapartum chemoprophylaxis for pregnant women 
colonized with S. agalactiae presenting with some 
of the risk factors for child contamination (preterm 
birth, membrane rupture time greater than or equal 
to 18 hours, body temperature higher than 38 ºC 
during labor) may significantly reduce the incidence 
of vertical infection2,10.
The Center for Disease Control (CDC) recommends 
that bacterial screening is performed routinely in a 
prenatal examination in pregnant women between 
35 and 37 weeks of gestation because colonization is 
transient. Microbiological screening is recommended 
through screening of the microorganism in samples 
of vaginal and rectal secretions from the pregnant 
woman in order to prevent possible infection of the 
neonate4,11.
Regardless of the clinical form of the neonatal 
streptococcal disease, chronic neurological sequelae 
are the major and most costly consequences among 
survivors. The presence of varied deficits and the 
continuous need for neurological and physical therapy, 
among others, make the treatment of sequelae in 
children onerous to health services and families1.
In the 1980s, a significant decrease in neonatal sepsis 
rates was observed with the use of chemoprophylaxis 
in pregnant women colonized by GBS. In 1996, in the 
United States, the CDC published guidelines for the 
prevention of GBS infection in the prenatal period12. 
In 2002, the CDC updated its pregnancy screening 
guidelines for detection of GBS colonization between 
35 and 37 weeks of gestation, indicating antibiotic 
prophylaxis in infections during labor13. In 2010, a 
new update on prevention strategies provided new 
guidelines regarding the rational use of antibiotics, 
screening, and laboratory methodology14,15.
The first choice is beta-lactam antibiotics given that 
S. agalactiae is sensitive to most of these antimicrobial 
agents, which have the same structure and mechanism 
of action, i.e., the inhibition of peptidoglycan bacterial 
cell wall synthesis. The group includes penicillins, 
cephalosporins, and carbapenems16. When the user 
is allergic to penicillin, erythromycin or clindamycin 
is chosen15,17. Erythromycin belongs to the group of 
macrolide antibiotics, while clindamycin belongs to 
the group of lincosamides16.
The problem of bacterial resistance to antibiotics is 
part of the evolution of microorganisms in the struggle 
for their own survival and consequent maintenance of 
the species18. Thus, indiscriminate use of antibiotics, 
even in cases of prophylaxis indication, may result 
in the selection of resistant bacteria, making it an 
increasing problem.
Considering the increasing number of neonatal 
infections caused by S. agalactiae, the present study 
evaluated the prevalence of this microorganism in 
samples from pregnant women collected at or referred 
to the Hermes Pardini Laboratory, as well as the 
susceptibility profile to erythromycin and clindamycin.
METHODS
The results of the survey for S. agalactiae from 
vaginal and perianal samples collected from January 
to April 2014 and from January to April 2015 were 
evaluated and compared. The data were collected 
through electronic records with reports of cultures 
performed in pregnant patients by the Microbiology 
department at the Hermes Pardini Laboratory.
Material collection and processing were performed 
according to the recommendations of the CDC, using 
a swab for each anatomical site and Stuart transport 
medium at room temperature. The time elapsed 
between collection and processing of the material 
was approximately 48 hours.
In the Microbiology department, the materials were 
inoculated in Columbia CNA agar (agar base + 5% 
sheep blood added with 0.01g/L colistin and 0.015g/L 
nalidixic acid, bioMérieux, Brazil). The sample was 
sown on a portion of CNA agar and striated to obtain 
isolated colonies. The samples were also seeded in 
thioglycolate broth.
The CNA agar plates were incubated in 5% CO2 
atmosphere at 35 ± 2 °C for 48 hours. The thioglycolate 
broth was incubated in a bacteriological oven at 
35 ºC for 24 hours. After the incubation period, the 
thioglycolate broth was quenched on CNA agar and 
the plates were incubated for 24 hours at 35 ± 2 °C 
at 5% CO2.
Plates showing colonies with beta-hemolytic 
streptococcal characteristics (Figure 1) were 
considered positive cultures. Plates not showing 
colonies with these characteristics were considered 
negative cultures.
Positive cultures were sent for antibiogram and 
bacterial identification. The antimicrobial susceptibility 
test was performed on a Muller-Hilton blood plate 
(Mueller-Hinton agar with 5% sheep blood, bioMérieux, 
Brazil), and paper discs impregnated with antibiotics 
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were inoculated (Figure 2). Antibiogram results were 
analyzed after 24 hours of incubation at 35 ± 2 ºC in 
the CO2 atmosphere.
For bacterial identification, the SlidexStrepto plus 
kit (bioMérieux, Brazil) – Rapid agglutination test of 
latex microparticles was used to classify beta-hemolytic 
streptococci according to the Lancefield classification. 
Quality control of culture media and antibiotic disks 
was performed using the Streptococcus pneumoniae 
strain ATCC 49619 following the recommendations 
of the Clinical and Laboratory Standards Institute19,20.
RESULTS AND DISCUSSION
The study sample consisted of 29,875 pregnant 
women who underwent specific GBS screening, 
14,442 in 2014 and 15,433 in 2015. A total of 26.8% 
(3,866) and 26.1% (4,022) positive cultures were 
found in 2014 and in 2015, respectively (Figure 3). 
These percentages can be translated into the 
number of children that could be born colonized 
with this bacterium and, later on, develop serious 
and irreversible sequelae.
Prevention is of extreme importance in areas of 
high incidence of invasive disease by beta-hemolytic 
GBS. Administering chemoprophylaxis to all pregnant 
women and newborns is impracticable. The challenge, 
therefore, is to correctly identify high-risk pregnancies. 
The most effective way to prevent early-onset neonatal 
infection is administering antibiotics during labor. 
However, there is no evidence that chemoprophylaxis 
prevents late-onset infection14,21,22.
The high frequencies found in this study (26.8% 
and 26.1%) are in accordance with the literature 
showing average colonization ranging from 10 to 30% 
in different locations23,24. Knowledge of local profiles 
of antimicrobial susceptibility is of great importance 
because it allows the clinician to provide with more 
certainty the empirical treatment of chemoprophylaxis 
when indicated. For intrapartum prophylaxis, penicillin 
and/or ampicillin are recommended as drugs of 
choice. Cefazolin is recommended when the pregnant 
woman is allergic to penicillin and presents a low risk 
of anaphylaxis. If the risk of anaphylaxis is high, the 
use of erythromycin or clindamycin is recommended. 
Vancomycin is an alternative drug for patients allergic 
to penicillin4.
Figure 1: Colonies of S. agalactiae on a CNA agar plate.
Figure 2: Antimicrobial susceptibility test of S. agalactiae 
on a Mueller-Hinton agar plate with 5% sheep blood. Figure 3: Prevalence of group B streptococcus (GBS).
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In this study, levels of resistance to erythromycin 
and clindamycin were, respectively, 2.4% and 5.5% in 
2014 and 3.2% and 6.5% in 2015 (Figure 4). Regarding 
erythromycin, levels of resistance achieved 30% in 
the United States, 21.4% in France, 20% in Turkey, 
and 10.7% in Portugal. These values are  higher than 
those detected in the present study, suggesting a 
variation of resistance across different populations. 
Clindamycin showed resistance generally lower than 
that of erythromycin in other countries, including 
17.5% in France, 11.4% in the United States, and 
9.9% in Portugal4,23,25.
Although the present study demonstrated a lower 
resistance profile for erythromycin and clindamycin 
than comparative studies in other countries, there are 
reports of increased resistance to these antimicrobials16, 
which is of concern, as they may be the choice for 
patients allergic to penicillin. Considering that S. 
agalactiae remains sensitive to penicillin, the use 
of clindamycin and erythromycin is associated with 
considerable worries, as resistant strains have been 
found ranging from 1 to 26%12.
Anaphylactic reactions as adverse effects of 
antibiotic use are also a cause for concern14,22. 
Therefore, epidemiological studies of S. agalactiae 
colonization should be performed to assess which 
chemoprophylaxis should be implemented and thus 
optimize the risk/benefit of this. In Brazil, screening 
for GBS colonization is not part of the prenatal care 
protocol proposed by the Ministry of Health26. Thus, 
knowing the incidence of GBS colonization in pregnant 
women is essential.
CONCLUSION
S. agalactiae is a microorganism whose presence 
should be investigated and, when found, reported to 
the clinician in charge. The treatment usually does 
not present many difficulties, but lack of it may cause 
serious consequences for newborns.
Erythromycin and clindamycin are antibiotics 
of particular importance in therapy. As with other 
drugs, an increase in bacterial resistance to these 
antibiotics has been found, making it imperative 
to monitor sensitivity profiles over the years and 
in each specific population group, as undesirable 
therapeutic failures may occur, as well as reduction 
of treatment options.
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Figure 4: Frequency of resistance of S. agalactiae to 
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